The risk for recurrent cardiovascular events is high among patients with r-axSpA and a history of these events, though TNF inhibitor therapy may offer protective benefits.
Bimekizumab improves pain, morning stiffness, and fatigue in axial spondyloarthritis patients, with sustained benefits over a ...
MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...
ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram ...
Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show ...
AxSpA can bring on plantar fasciitis, which is when inflammation in the heel causes the sole of your foot to hurt. You may ...
MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Multiple Sclerosis.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Upadacitinib vs placebo demonstrated lasting efficacy and safety over 52-weeks of treatment among patients with nr-axSpA.
Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...
TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback